PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28715249-0 2017 Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. ibrutinib 148-157 CD19 molecule Homo sapiens 74-78 26813675-4 2016 We found that >=5 cycles of ibrutinib therapy improved the expansion of CD19-directed CAR T cells (CTL019), in association with decreased expression of the immunosuppressive molecule programmed cell death 1 on T cells and of CD200 on B-CLL cells. ibrutinib 31-40 CD19 molecule Homo sapiens 75-79 23940282-0 2013 Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. ibrutinib 114-123 CD19 molecule Homo sapiens 10-14 27677739-0 2017 Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. ibrutinib 17-26 CD19 molecule Homo sapiens 75-79 28715249-12 2017 Conclusion CD19 CAR-T cells are highly effective in high-risk patients with CLL after they experience treatment failure with ibrutinib therapy. ibrutinib 125-134 CD19 molecule Homo sapiens 11-15 32563910-9 2020 Ibrutinib was biologically active, since hCD19+ cells harvested from ibrutinib treated mice had no detectable levels of phospho-BTK at tyrosine 223 (pBTK Y223), whereas pBTK Y223 was still detectable in placebo treated cases. ibrutinib 0-9 CD19 molecule Homo sapiens 41-46 33661190-13 2021 Ibrutinib significantly suppressed proliferating (Ki67+) CD19+ peripheral blood mononuclear cells and had no significant effect on other lymphocyte subsets. ibrutinib 0-9 CD19 molecule Homo sapiens 57-61 32861289-5 2020 We review preliminary safety and efficacy data of 2 pivotal trials investigating the use of CD19-targeted CAR-T cells for R/R MCL after ibrutinib failure and discuss potential timing of these approaches. ibrutinib 136-145 CD19 molecule Homo sapiens 92-96 33932067-0 2021 Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. ibrutinib 0-9 CD19 molecule Homo sapiens 40-44 33932067-8 2021 The successful outcome of the second-time anti-CD19-CAR T-cell therapy might suggest that the previous ibrutinib treatment improved the activities of anti-CD19-CAR T cells. ibrutinib 103-112 CD19 molecule Homo sapiens 47-51 33932067-8 2021 The successful outcome of the second-time anti-CD19-CAR T-cell therapy might suggest that the previous ibrutinib treatment improved the activities of anti-CD19-CAR T cells. ibrutinib 103-112 CD19 molecule Homo sapiens 155-159 32876369-1 2020 Ibrutinib might improve the efficacy of anti-CD19 chimeric antigen receptor (CD19 CAR) T cell therapy in chronic lymphocytic leukemia (CLL). ibrutinib 0-9 CD19 molecule Homo sapiens 45-49 32876369-1 2020 Ibrutinib might improve the efficacy of anti-CD19 chimeric antigen receptor (CD19 CAR) T cell therapy in chronic lymphocytic leukemia (CLL). ibrutinib 0-9 CD19 molecule Homo sapiens 77-81 32876369-3 2020 In this study, we selected the CD19 CAR-T cells of a patient with lymphoma who failed in his CD19 CAR-T cell therapy and a dose of 8 mg/kg/day ibrutinib. ibrutinib 143-152 CD19 molecule Homo sapiens 31-35 32581054-5 2020 RESULTS: Here, we report that a bispecific CD3xCD19 DART mediates efficient killing by HD T cells of CD19+ cell-lines and primary CLL cells, regardless of immunoglobulin heavy chain variable region (IGHV) mutational status TP53 status or chemotherapy, ibrutinib or venetoclax sensitivity. ibrutinib 252-261 CD19 molecule Homo sapiens 43-51 32581054-5 2020 RESULTS: Here, we report that a bispecific CD3xCD19 DART mediates efficient killing by HD T cells of CD19+ cell-lines and primary CLL cells, regardless of immunoglobulin heavy chain variable region (IGHV) mutational status TP53 status or chemotherapy, ibrutinib or venetoclax sensitivity. ibrutinib 252-261 CD19 molecule Homo sapiens 47-51 31899702-0 2020 Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib. ibrutinib 121-130 CD19 molecule Homo sapiens 29-33 31899702-8 2020 A combination of the defined cell product therapy candidate, liso-cel, with ibrutinib or acalabrutinib is an attractive approach that may potentiate the promising clinical responses already achieved in CD19 B-cell malignancies with each of these single agents. ibrutinib 76-85 CD19 molecule Homo sapiens 202-206 29743179-0 2018 A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. ibrutinib 98-107 CD19 molecule Homo sapiens 2-6 29743179-10 2018 We next explored the activity of CD19/CD3-scFv-Fc in the context of ibrutinib treatment and ibrutinib resistance. ibrutinib 68-77 CD19 molecule Homo sapiens 33-37 29743179-11 2018 CD19/CD3-scFv-Fc induced more rapid killing of CLL cells from ibrutinib-treated patients than those from treatment-naive patients. ibrutinib 62-71 CD19 molecule Homo sapiens 0-4 29743179-12 2018 CD19/CD3-scFv-Fc also demonstrated potent activity against CLL cells from patients with acquired ibrutinib-resistance harboring BTK and/or PLCG2 mutations in vitro and in vivo using patient-derived xenograft models. ibrutinib 97-106 CD19 molecule Homo sapiens 0-4